Repositioning Candidate Details
| Candidate ID: | R1337 |
| Source ID: | DB11114 |
| Source Type: | approved |
| Compound Type: | biotech |
| Compound Name: | Eucalyptus oil |
| Synonyms: | Blue gum leaf oil; Dinkum oil; Eucalyptus essential oil; Eucalyptus globulus leaf essential oil; Eucalyptus globulus leaf oil; Eucalyptus globulus leaf water; Eucalyptus globulus leaf/twig oil; Eucalyptus globulus oil; Eucalyptus globulus oil burundia; Eucalyptus globulus oil pakistan; Eucalyptus globulus oil rwanda; Eucalyptus globulus oil zambia; Eucalyptus leaf oil; Eucalyptus oil; Eucalyptus terpene oil; Eucalyptus volatile oil; Oil of eucalyptus; Southern blue gum leaf oil; Tasmanian blue gum leaf oil |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Eucalyptus oil is a distilled oil derived from the leaves of the tree Eucalyptus. It is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response. It is also shown to exhibit antibacterial activity against some bacterial species and cough suppressant actions. Eucalyptus oil can be applied directly to the skin for pain and swelling of respiratory tract mucous membranes, joint pain, genital herpes, and nasal stuffiness. |
| CAS Number: | 8000-48-4 |
| Molecular Weight: | |
| DrugBank Indication: | As an active agent, eucalyptus oil has been indicated for relief of the symptoms of catarrhal colds, and/or the relief of the symptoms of minor muscular sprains and cramps . |
| DrugBank Pharmacology: | Lipophilic monoterpene formulations of eucalyptus oil appear to be readily absorbed orally, with a primarily oxidative metabolism that might necessitate induction of the cytochrome P450 enzyme system and subsequent urinary excretion . Gastrointestinal absorption of eucalyptus appears to be rapid and may be enhanced by the intake of lipids and milk. 1,8-cineole (which makes up to as much as 90% of most commonly used cineole-based eucalyptus oils) has also been found in vitro and in animals to possess cytochrome P450 inducing activity . |
| DrugBank MoA: | The general consensus is that the exact mechanism of action of eucalyptus oil is largely unknown at this time but comprises various hypotheses from various studies. Cineol containing preparations of eucalyptus oil may contain up to 80% (or more) 1,8-cineole and is one of the most common types of eucalyptus oil formulations used. As an active agent indicated for relieving certain cold symptoms and/or certain muscular sprains and cramps, it is believed that eucalyptus oil may possess some antimicrobial and anti-inflammatory activities. Some in vitro studies of human blood monocytes suggest a dose-dependent effect of eucalyptus oil to elicit significant inhibition of multiple cytokines, perhaps in the treatment of airway inflammation . Moreover, other studies in animal models discuss the possibility of eucalyptus oil demonstrating anti-inflammatory and anti-nociceptive effects that potentially account for inhibiting the formation of prostaglandins and cytokines by stimulated monocytes in vitro . Furthermore, additional studies have observed eucalyptus oil anti-viral activity against herpes simplex virus (HSV-1, HSV-2) in cell cultures as well as the demonstration of broad antimicrobial activity of eucalyptus medicinal plant extracts against Alicyclobacillus acidoterretris, Bacillus cereus, E. coli, Enterococcus faecalis, MRSA, Propionibacterium acnes, S. aureus, fungus including C. albicans isolates, Trichophyton mentagrophytes, and other Gram-positive bacteria. Specific activity against periodontopathic bacteria, such as Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans, Fusobacterium nucleatum, Streptococcus mutans, and Streptococcus sobrinus has also been observed . |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|